which is currently given via intravenous (i.v.) infusion. As a line extension, it expands the blockbuster drug franchise and extends the patent protection for Herceptin—a strategy Roche could ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

[54] Trastuzumab should not be administered as an i.v. push or bolus infusion. Trastuzumab is available as a preservative- free lyophilized powder for i.v. injection. The drug is formulated in ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is a brand-name drug prescribed for certain cancers. Enhertu comes as an intravenous (IV) infusion given by a healthcare professional. The dosage can vary ...